| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Digestive System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Digestive System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Digestive System |
Recent Updates
Recently added Catalysts
Protalix BioTherapeutics, Inc. (DE)$2.44
+0.07 (+2.95%)
C 42Pipeline Score Fair Value Biotech · Clinical
Market Cap
169.20 M
EPS
0.19
P/E Ratio
11.46 $
Value Trade
1.64 M
SEC Financials
Q1 2026Dilution Risk
Revenue
33.75 M
R&D Expenses
5.43 M
Operating CF
22.02 M
Total Assets
102.34 M
Total Liabilities
35.11 M
Equity
67.23 M
D/E Ratio
12,345
5 %
Week
-5.41 %
1 Month
-33.33 %
3 Month
22.81 %
6 Month
-28.08 %
5 Year
-99.97 %
All Time
Cash Data
Cash Position
41.00 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
678.25 K
52 Week Range
1.32 - 3.19
% held by Insiders
3.88 %
% held by Institutions
21.86 %
Enterprise Value
125.89 M
Total Shares
80.41 M
Short %
4.97 %
Float Shares
71.57 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Protalix BioTherapeutics, Inc. (DE)
710Total events
10Upcoming
230Tier-1 (high impact)
2007 – 2028Coverage
Upcoming catalysts 10
2028
T2Pipeline Prioritization
3-year goal: 5-7 programs spanning discovery to clinic in rare renal diseases
TBD
T2Milestone Payment
Protalix eligible for $25M regulatory milestone payment from Chiesi upon EC approval
2025-2027
T1Partnership / License
Business development activities for rare renal diseases partnership
TBD
T2Milestone Payment
Significant milestone payments expected in mid- and long-term from Chiesi partnership
Event history 700
May 21, 2026
May 2026
▲MHRA MilestoneElfabrioApprovedEx-US Regulatory
MHRA approved 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults with Fabry disease
Fabry diseasesource ↗
Mar 18, 2026
▲EU ApprovalElfabrioApprovedEx-US Regulatory
EC approved E4W dosing regimen for Elfabrio
Fabry diseasesource ↗
Mar 18, 2026
Mar 9, 2026
▲EU ApprovalElfabrioApprovedEx-US Regulatory
European Commission approval of 2mg/kg every-4-weeks dosing regimen for Elfabrio
Fabry diseasesource ↗
Mar 9, 2026
▲CHMP Positive OpinionElfabrioApprovedEx-US Regulatory
CHMP positive opinion recommending additional dosing regimen for Elfabrio
Fabry diseasesource ↗
Mar 9, 2026
▲Milestone PaymentElfabrioApprovedCorporate
Protalix entitled to $25 million regulatory milestone payment from Chiesi
Fabry diseasesource ↗
Mar 2026
◆EU ApprovalElfabrioApprovedEx-US Regulatory
EC decision anticipated for Elfabrio every-4-weeks dosing regimen
Fabry diseasesource ↗
Mar 2026
▲Milestone PaymentElfabrioApprovedCorporate
Regulatory milestone payment from Chiesi upon EC approval of Elfabrio E4W dosing
Fabry diseasesource ↗
Jan 30, 2026
▲CHMP Positive OpinionElfabrioApprovedEx-US Regulatory
CHMP positive opinion for Elfabrio every-4-weeks dosing regimen
Fabry diseasesource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $204M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored1.2x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankProtalix BioTherapeutics, Inc. (DE) carries a moderate pipeline score (42/100), with $816M risk-adjusted pipeline value, led by Pegunigalsidase alfa in Fabry Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pegunigalsidase alfa Monoclonal antibody | Fabry Disease | Phase 3 | NCT03180840 | 61% | $238M | COMPLETED | 30 | - | - | Jul 1, 2020 | - | Sep 12, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PRX-115 | uncontrolled gout | Phase 1 | 2024-08-14 | Results from the first seven cohorts of the phase I clinical trial of PRX-115 for the treatment of uncontrolled gout are encouraging. Read More | Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. Read More | |
PRX-115 | uncontrolled gout | Phase 1 | 2024-08-14 | Results from the first seven cohorts of the phase I clinical trial of PRX-115 for the treatment of uncontrolled gout are encouraging. Read More | Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. Read More | |
PRX-115 | uncontrolled gout | Phase 1 | 2024-08-14 | Results from the first seven cohorts of the phase I clinical trial of PRX-115 for the treatment of uncontrolled gout are encouraging. Read More | Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PLX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PLXPROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 20
Protalix Biotherapeutics presented updates on its pipeline and financial status in June 2024, highlighting advanced clinical stages for drugs targeting rare diseases. The company aims to capitalize on the growing market for therapies such as Elfabrio, which is expected to capture significant market share in treating Fabry disease. Additionally, promising data from the ongoing Phase 1 study of PRX-115 for uncontrolled gout reinforces its best-in-class potential and is anticipated to drive future growth. Protalix's strong partnership with Chiesi and solid financial position further underpin its strategic goals in rare disease treatments.
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission
Protalix BioTherapeutics reported its first quarter 2026 financial results, highlighting positive momentum with ongoing partnerships and clinical advancements. The company reaffirmed its strategic priorities and financial outlook, driven by recent regulatory achievements for its product Elfabrio and continued enrollment in clinical studies for its candidate PRX-115. The management emphasized a strong financial position and a focus on developing therapies for rare diseases. Despite the positive outlook, they acknowledged various risks associated with commercialization and potential disruptions due to regional conflicts.
Read more →PLX▼ -20.8%on this news
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dos
Protalix BioTherapeutics reported its fiscal year 2025 financial and business results, highlighting important advancements such as the European Commission's approval of the E4W dosing regimen for its product Elfabrio. The company emphasized a strong commercial outlook and the progress of its clinical pipeline, including the active enrollment in Phase 2 trials for PRX-115. As they move into 2026, Protalix aims to enhance profitability and expand its product offerings in rare diseases, while acknowledging existing risks related to market dynamics and regulatory challenges.
Read more →PLX▲ +9.9%on this news
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Commission has approved a new dosing regimen for Elfabrio (pegunigalsidase alfa) for adults with Fabry disease. The regimen allows for administration every four weeks instead of every two weeks, providing greater flexibility for patients. This decision follows a positive opinion from the EMA and aims to ease the treatment burden for patients and their families.
Read more →PLX▲ +8.1%on this news
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, an
Protalix Biotherapeutics is advancing its initiatives with Elfabrio for Fabry disease, which recently received positive opinion from the EMA for an expanded dosing regimen. The company is strengthening its position in the market through strategic partnerships, particularly with Chiesi, providing a robust foundation for growth. Additionally, Protalix is actively enrolling patients in the Phase 2 trial for PRX-115, a treatment for uncontrolled gout, aiming to address significant unmet medical needs in this area.
Read more →PLX▲ +13%on this news· ran to +40% by day 3
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU Committee for Medicinal Products f
Chiesi Global Rare Diseases and Protalix BioTherapeutics received a positive recommendation from the CHMP for an every-four-week dosing regimen of Elfabrio (pegunigalsidase alfa) for Fabry disease treatment. This follows a re-examination and could greatly reduce the treatment load for patients currently required to visit infusion centers every two weeks. Although the new regimen is not approved in the U.S., it represents a significant step forward in treatment flexibility and patient care. A decision from the European Commission is expected by March 2026.
Read more →PLXProtalix BioTherapeutics Letter to Stockholders
Protalix BioTherapeutics provided an update expressing its focus on growth and innovation for rare diseases in 2026. The company highlighted the promising results of PRX-115 for uncontrolled gout, which could address significant treatment gaps. Additionally, Protalix is strengthening its renal pipeline with PRX-119. The company also noted solid commercial performance through its collaborations with Chiesi and Pfizer, despite facing a negative opinion from EMA regarding Elfabrio, necessitating an appeal.
Read more →PLX▼ -9.8%on this news
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m.
Protalix BioTherapeutics has reported its financial results for the third quarter of 2025, indicating total revenues of $17.9 million and a 24% increase in revenues for the first nine months compared to the previous year. CEO Dror Bashan highlighted the encouraging data from the company's phase 1 clinical trial of PRX-115, suggesting its potential as an innovative treatment for uncontrolled gout. Furthermore, Protalix maintains a robust cash position of $29.4 million, adequate for at least the next year, although revenues showed a slight decline in the recent quarter compared to 2024. The company is planning to initiate a phase 2 trial for PRX-115 later this year.
Read more →PLXChiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU -- Every two
Chiesi Global Rare Diseases and Protalix BioTherapeutics are requesting a re-examination by the EMA regarding a negative opinion on an alternative dosing regimen for Elfabrio (pegunigalsidase alfa). The proposed regimen involves infusing 2 mg/kg every four weeks, whereas the existing regimen of 1 mg/kg every two weeks remains approved. The companies aim to address the unmet medical needs of patients with Fabry disease throughout this process. Notably, the existing marketing authorization for Elfabrio stays in force while the re-examination is pending.
Read more →PLX▲ +5.8%on this news
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Protalix BioTherapeutics, Inc. (NYSE American:PLX) announced that its President and CEO, Dror Bashan, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The conference, held at the Lotte New York Palace Hotel, will include one-on-one meetings between management and registered investors. Protalix focuses on developing recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression system and has recently gained FDA approval for its second product, Elfabrio.
Read more →PLX▼ -5.6%on this news
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics reported strong financial results for Q2 2025, showcasing a 50% increase in revenues driven mainly by the sales of Elfabrio. The company highlights a promising partnership with Chiesi for commercialization efforts in the Fabry disease market, anticipated to grow significantly by 2030. Additionally, Protalix is preparing to launch a Phase 2 trial for PRX-115, a treatment targeting uncontrolled gout. However, the company remains cautious about potential fluctuations in product orders and the impact of regional conflicts on operations.
Read more →PLXProtalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Protalix BioTherapeutics has appointed Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok brings three decades of experience in healthcare and technology, succeeding Eyal Rubin, who will assist during the transition until October 2025. The leadership change is expected to support Protalix's growth strategy.
Read more →PLXProtalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer C
Protalix BioTherapeutics has appointed Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025. He succeeds Eyal Rubin, who will assist in the transition until October 2025. Mamlok has extensive experience in healthcare finance and is expected to contribute significantly to the company's growth strategy. The company has recently experienced momentum with the approval of its product Elfabrio and has a robust development pipeline.
Read more →PLX▼ -40.5%on this news
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics reported strong first quarter results for 2025, with revenues from goods increasing by 170% compared to the previous year. The company highlighted progress in its clinical pipeline, particularly the promising results of PRX-115 from its Phase I trial for gout, indicating plans to proceed to a Phase II trial later this year. Despite these positive developments, the company reported a net loss of approximately $3.6 million for the quarter, and the cost of goods sold has seen a significant increase.
Read more →PLX▲ +9.4%on this news
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics reported strong fiscal results for 2024, citing record revenues from multiple streams. The company's ongoing trials for PRX-115 show promise, with plans to advance to phase II clinical trials in 2025. Furthermore, Protalix has successfully repaid all debts, enhancing its financial stability. However, the company faces risks related to the commercialization of its products and potential disruptions from regional instability.
Read more →PLXProtalix BioTherapeutics Issues 2025 Letter to Stockholders
Protalix BioTherapeutics reported a positive outlook in its 2025 letter to stockholders, highlighting significant achievements in 2024, including advancements in its treatment pipeline. The company is particularly optimistic about its PRX-115 trial for uncontrolled gout and its ongoing collaboration with Chiesi Global Rare Diseases to lessen the treatment burden for Fabry disease. Additionally, their debt-free status positions the company well financially, despite challenges from the current military situation in Israel. Protalix plans to continue sharing developments as it focuses on renal rare diseases moving forward.
Read more →PLX▲ +13.7%on this news· ran to +31% by day 3
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics has announced its financial results for Q3 2024 and provided an update on its product pipeline. The company reported completion of all cohorts in a phase I clinical trial for PRX-115, a candidate for uncontrolled gout treatment, which indicated encouraging preliminary results. Protalix plans to initiate a phase II study in the second half of 2025. Although the results are promising, further research is necessary to confirm the long-term effectiveness and safety of PRX-115.
Read more →PLXProtalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Protalix BioTherapeutics announced the presentation of Phase I clinical trial data for PRX-115, a recombinant PEGylated uricase product candidate targeting uncontrolled gout. The data will be showcased in a late-breaking poster session at ACR Convergence 2024, set for November 14-19, 2024, in Washington, D.C. This event highlights the company's ongoing commitment to developing innovative therapies supported by their proprietary ProCellEx protein expression system.
Read more →PLX▼ -10.6%on this news
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics reported its financial results for Q2 2024, highlighting progress in its early-stage pipeline. Positive data from the phase I clinical trial of PRX-115 for uncontrolled gout has prompted plans for a phase II trial. The company also indicated a solid financial position, allowing for the repayment of convertible notes due in September 2024. Protalix remains focused on managing ongoing business despite challenges posed by external conflicts.
Read more →PLX▼ -12%on this news
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics (PLX) reported its financial results for the first quarter of 2024, highlighting encouraging initial results from its phase I clinical trial of PRX-115 for uncontrolled gout. The company announced plans to expand the trial by adding an eighth cohort for further analysis. Despite a strong cash position, Protalix reported a significant decrease in revenues and an increased net loss compared to the same period in the previous year. A conference call is scheduled to discuss these results and future business updates.
Read more →PLX▼ -9.9%on this news
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics, Inc. reported financial results for fiscal year 2023, highlighting the approval of Elfabrio for treating Fabry disease. The company continues its partnership with Chiesi Global Rare Diseases for commercial success and has initiated a phase I trial for PRX-115, a treatment for severe gout. While there are promising developments, the company faces potential operational risks and market acceptance challenges. A conference call to discuss these results is scheduled for today at 8:30 AM EDT.
Read more →PLXProtalix BioTherapeutics Issues 2024 Letter to Stockholders
Protalix BioTherapeutics has issued a 2024 letter to stockholders highlighting significant milestones, including FDA and EMA approval of Elfabrio for Fabry disease. The company is progressing with its clinical trials, notably for PRX-115 against severe gout. A strategic partnership with Chiesi Global Rare Diseases has been pivotal in launching Elfabrio. However, challenges remain due to the geopolitical situation in Israel, which could affect operations and market acceptance.
Read more →PLX▼ -18.4%on this news
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics has released its financial results for the third quarter of 2023, highlighting the approval of Elfabrio for Fabry disease treatment and ongoing clinical trials for PRX-115 aimed at treating severe gout. The company emphasizes its strong financial position and the progress made in regulatory and clinical developments. It also announced the appointment of Eliot Richard Forster as the new Chairman of the Board. Protalix aims to continue its momentum by focusing on the commercialization of its products and growing its pipeline of therapeutic candidates.
Read more →PLXProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors Appointment effective as of
Protalix BioTherapeutics has appointed Eliot Richard Forster, Ph.D., as the new Chairman of its Board of Directors effective September 14, 2023. This transition follows the retirement of Zeev Bronfeld, who played a crucial role in the company's early development and the approval of its first two treatments. Dr. Forster, with a rich background in the life sciences and numerous leadership roles, expresses excitement about Protalix's future. The company focuses on recombinant therapeutic proteins and has recently achieved significant milestones with its product pipeline.
Read more →PLXProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Protalix BioTherapeutics has appointed Eliot Richard Forster, Ph.D., as the new Chairman of its Board of Directors, effective September 14, 2023. Forster, who has a strong background in the life sciences sector, replaces Zeev Bronfeld, who will retire after nearly three decades with the company. The leadership change is expected to enhance Protalix's research and development efforts.
Read more →PLX▲ +14.5%on this news
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m.
Protalix BioTherapeutics announced its financial results for Q2 2023 and highlighted significant advancements, notably the regulatory approval of Elfabrio for treating adult patients with Fabry disease in the U.S. and EU. The company, in collaboration with Chiesi Global Rare Diseases, has successfully launched Elfabrio, marking a pivotal moment for Fabry disease patients. Protalix is now focused on enhancing its pipeline for rare diseases and pursuing further growth opportunities as it continues to navigate market challenges.
Read more →PLXProtalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Protalix BioTherapeutics, Inc. announced that CEO Dror Bashan will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The conference is taking place from August 7-10, 2023, in Boston, MA. Bashan's presentation will provide a corporate overview, and management will hold one-on-one meetings with registered investors. Protalix is focused on developing therapeutic proteins using its proprietary ProCellEx plant cell-based expression system, having already received FDA approval for products like Elfabrio and taliglucerase alfa.
Read more →PLXProtalix BioTherapeutics Issues Letter to Stockholders
Protalix BioTherapeutics has issued a letter to stockholders celebrating the recent approval of Elfabrio for Fabry disease treatment in both the US and EU. CEO Dror Bashan highlighted the significance of this milestone and expressed confidence in commercial partner Chiesi Global Rare Diseases for a successful launch. Protalix also looks forward to future pipeline programs, promising to engage with investors at an upcoming event. The letter reflects gratitude for investor support while acknowledging potential future risks in commercialization and development processes.
Read more →PLX▼ -9.3%on this news
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases Milestone payment triggered by FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) and payable within 30 days of approval
Protalix BioTherapeutics announced a $20 million milestone payment from Chiesi Global Rare Diseases triggered by the FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) for Fabry disease. This payment, due within 30 days of approval, will enhance Protalix's financial standing. The collaboration with Chiesi leverages their global expertise for further commercialization of Protalix's products. As of May 18, 2023, Protalix's cash and cash equivalents, including this payment, amount to $51.6 million.
Read more →PLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease - PEGylated enzyme replacement therapy designed to p
Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) for the treatment of adult patients with Fabry disease. ELFABRIO is a PEGylated enzyme replacement therapy designed to offer a long half-life and a viable alternative to existing treatments. The approval follows a comprehensive clinical development program involving over 140 patients, indicating a promising safety and efficacy profile. The release emphasizes the ongoing need for new treatment modalities for Fabry disease, particularly for diverse patient presentations.
Read more →PLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease - PEGylated enzyme replacement therap
Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the European Commission has granted marketing authorization for PRX-102 (pegunigalsidase alfa) to treat adult patients with Fabry disease. This approval is based on a comprehensive clinical development program involving over 140 patients, demonstrating effective treatment outcomes. Both companies expressed their commitment to meet the needs of Fabry patients and ensure access to this innovative therapy. PRX-102 is currently under FDA review in the U.S., but has not yet been approved there.
Read more →PLX▲ +6.7%on this newsshared move
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT C
Protalix BioTherapeutics has reported its financial and business results for the first quarter of 2023, highlighting significant advancements in their clinical programs, particularly PRX-102 for Fabry disease and the initiation of a Phase I trial for PRX-115 aimed at severe gout. The company is awaiting decisions from the European Commission and FDA, and emphasizes its dedication to improving patient outcomes. Financially, Protalix has shown an increase in cash reserves compared to the previous quarter, suggesting a stable operational footing as they advance their pipeline.
Read more →PLXProtalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST C
Protalix BioTherapeutics reported its fiscal year 2022 financial results and provided a business update, highlighting a positive opinion from the EMA regarding the marketing authorization for PRX-102, aimed at treating Fabry disease. The company anticipates potential regulatory approvals from both the EMA and FDA by May 2023, following successful phase III clinical trials. Protalix aims to advance its drug pipeline while acknowledging risks tied to future regulatory outcomes and commercial success.
Read more →PLX▲ +7.1%on this newsshared move
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease - European Commission decision anticipated in beginning of May 2023 - PARMA/B
Chiesi Global Rare Diseases and Protalix BioTherapeutics have received a positive opinion from the EMA's CHMP for PRX-102, an enzyme replacement therapy for Fabry disease. This opinion recommends marketing authorization, with a final decision from the European Commission expected in May 2023. The therapy has shown a favorable benefit-risk profile based on extensive clinical trial data. Both companies are optimistic about delivering this new therapeutic option to patients suffering from Fabry disease.
Read more →PLXProtalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023
Protalix BioTherapeutics announced its participation in the 19th Annual WORLDSymposium 2023, scheduled for February 22-26 in Orlando, Florida. The company will host an informational booth, while its commercialization partner, Chiesi Global Rare Diseases, will present on PRX-102 and Fabry disease. This event highlights Protalix's commitment to advancing its therapeutic pipeline.
Read more →PLXProtalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023 Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...
Protalix BioTherapeutics, Inc. has scheduled a conference call for February 27, 2023, to discuss its fiscal year 2022 financial results and provide a business update. The call will be accessible via toll-free numbers and webcast, highlighting the company's commitment to shareholder engagement. Protalix is known for its proprietary ProCellEx® plant cell-based protein expression system, which has seen success with its first product, taliglucerase alfa, approved by the FDA in 2012. The company is actively engaged in developing additional therapeutic proteins for various diseases.
Read more →PLXProtalix BioTherapeutics Issues 2023 Letter to Stockholders
Protalix BioTherapeutics announced its 2023 letter to stockholders, reflecting on a productive 2022. The company's President and CEO highlighted key regulatory milestones for PRX-102, including Marketing Authorization Applications submitted to the EMA and FDA. Positive results from phase III trials support the treatment's efficacy for Fabry disease, suggesting potential approval and commercialization could occur in 2023. Additionally, Protalix is advancing its PRX-115 program for severe gout treatment, aiming to initiate a phase I clinical trial soon.
Read more →PLXProtalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange The Company's Common Stock will continue to trade on the NYSE American
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange The Company's Common Stock will continue to trade on the NYSE American CARMIEL, Israel, December 21, 2022 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmac
Read more →PLXProtalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
Protalix BioTherapeutics reported its financial results for Q3 2022 and highlighted the resubmission of the BLA for PRX-102 to the FDA. The CEO emphasized the potential impact of PRX-102 on patients with a rare genetic disease. The company is committed to bringing new medicines to patients and will host a conference call to discuss these developments.
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT C
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 15, 2022 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company
Read more →PLXProtalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors
Protalix BioTherapeutics has appointed Dr. Shmuel "Muli" Ben Zvi to its Board of Directors. Dr. Ben Zvi brings a wealth of experience in finance and management, having held various significant positions in the pharmaceutical industry. His appointment is expected to enhance the company's strategic execution as it continues to develop its proprietary therapeutic proteins.
Read more →PLXProtalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease C
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease CARMIEL, Israel, May 26, 2022 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commer
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT C
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 16, 2022 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focu
Read more →PLX▲ +41.9%on this news
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease PRX-102 successfully met the primary endp
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority
Read more →PLXProtalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results Company to host conference call and webcast at 8:30 a.m. EDT C ARMIEL, Israel, March 31 , 2022 -- Protalix BioTherapeutics, Inc. (NYSE Amer
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 31, 2022 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on
Read more →PLXProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease C ARMIEL, Israel a
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel and BOSTON, February 24, 2022 -- Protalix BioTherapeutics, I
Read more →PLXProtalix BioTherapeutics Issues 2021 Letter to Stockholders
Protalix BioTherapeutics Issues 2021 Letter to Stockholders CARMIEL, Israel, December 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant t
Read more →PLXBioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update Company to host conference call and webcast today at 8:30 a.m.
BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TAS
Read more →PLX▲ +5.2%on this news
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease C ARMIEL, Israel and BOSTON, October 11 , 2021 /PRNewswire/ -- Protalix BioTherapeutics, In
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel and BOSTON, October 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical compa
Read more →PLXProtalix BioTherapeutics Announces Closing of Private Note Exchange
Protalix BioTherapeutics Announces Closing of Private Note Exchange CARMIEL, Israel, August 26, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update CARMIEL, Israel, August 16, 2021 - Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and co
Read more →PLX▼ -9.5%on this newsshared move
Protalix BioTherapeutics Announces Private Note Exchange
Protalix BioTherapeutics Announces Private Note Exchange CARMIEL, Israel, August 13, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeuti
Read more →PLXProtalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
Protalix BioTherapeutics will participate in a fireside chat on June 30, 2021, hosted by Zacks Investment Research. CEO Dror Bashan and CFO Eyal Rubin will discuss the company's developments and answer investor questions. The event will be held virtually, allowing broad access for interested parties.
Read more →PLXProtalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALAN
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial Protalix management to host conference
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update Management to host conference call and live webcast today at 8:30 am
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results Management to host conference call and live webcast today at 8:30 am EDT CARMIEL, Israel, May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical comp
Read more →PLXProtalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA CARMIEL, Israel and
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA CARMIEL, Israel and BOSTON, Mass. - April 28, 2021 - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on
Read more →PLXProtalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results In February 2021, announced positive top-line results from the Company's phase III BRIGHT clinical trial In December 2020, announced positi
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results In February 2021, announced positive top-line results from the Company's phase III BRIGHT clinical trial In December 2020, announced positive final results from the Company's phase III BRIDGE cli
Read more →PLXProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatme
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease Study achieved key objectives for safet
Read more →PLXProtalix BioTherapeutics Announces Proposed Public Offering of Common Stock
BioTherapeutics Announces Proposed Public Offering of Common Stock Israel, February 11, 2021 /PR Newswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant
Read more →PLXProtalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Announced FDA acceptance of BLA filing of PRX - 102 for the treatment of Fabry disease Top-line data from the BRIGHT stud
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Announced FDA acceptance of BLA filing of PRX-102 for the treatment of Fabry disease Top-line data from the BRIGHT study expected by end of first quarter, 2021 Management to hos
Read more →PLXProtalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
Protalix BioTherapeutics Regains Compliance NYSE American Continued Listing Standards CARMIEL, Israel, September 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and comme
Read more →PLXProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease a
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment Fabry Disease and Grants Priority Review CARMIEL, Israel, August 11, 202
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Announced positive top-line data in its Phase III BRIDGE study of PRX-102 for the Treatment of Fabry disease Submission
Protalix BioTherapeutics Reports Second Financial Results and Provides Business Announced positive top-line data in its Phase III BRIDGE study of PRX-102 for the Treatment of Fabry disease Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Adminis
Read more →PLXProtalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
Protalix BioTherapeutics Appoints Yael New Vice President, Research and Development CARMIEL, Israel, June 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company's new Vice Presi
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update Conference call and live webcast scheduled for Monday, June 1 st , 2020 at 8:30 am
Protalix BioTherapeutics Reports First Financial Results and Business Update Conference call and live webcast scheduled for Monday, June 1st, 2020 at 8:30 am EDT CARMIEL, Israel, June 1, 2020 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopha
Read more →PLXProtalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutic
Read more →PLXProtalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease Phase III BRIDGE open-label,
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment BRIDGE open-label, switch-over clinical trial met main objectives for indicates substantial improvemen
Read more →PLXProtalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement CARMIEL, Israel, March 18, 2020 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recomb
Read more →PLXProtalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results Conference call and live webcast scheduled for Thursday, March 12th, 2020 at 8:30 am
Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results Conference call and live webcast scheduled for Thursday, March 12th, 2020 at 8:30 am EDT CARMIEL, Israel, March 12, 2020 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX)
Read more →PLXProtalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease Private financing includes Israeli and U.S. investors to support Protalix's innovative drug development techn
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease Private financing includes Israeli and U.S. investors to support Protalix's innovative drug development technologies CARMIEL, Israel, March 12, 2020 -- Protalix Bi
Read more →PLXProtalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16 th Annual WORLD Symposium 2020 Phase I/II dose-ranging studies show high correlation between two Fa
Protalix BioTherapeutics Presents Key of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium 2020 CARMIEL, Israel, February 10, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical comp
Read more →PLXProtalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Protalix BioTherapeutics and Chiesi Farmaceutici "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel, February 6, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceuti
Read more →PLXProtalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors Pol Boudes, MD, brings extensive medical research and development experience in Fabry disease, orphan drugs and medica
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors Pol Boudes, MD, brings extensive medical research and development experience in Fabry disease, orphan drugs and medical innovation Gwen Melincoff brings extensive experience
Read more →PLXProtalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
Protalix BioTherapeutics Announces 1-for-10 CARMIEL, Israel, December 9, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produc
Read more →PLXProtalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
CARMIEL, Israel, Nov. 27, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® pla
Read more →PLXProtalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States FDA indicated that ex
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States FDA indicated that existing clinical data, nonclinical data, safety database
Read more →PLXProtalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update CARMIEL, Israel, November 7, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercializati
Read more →PLXProtalix BioTherapeutics Announces Positive 12-Month Interim Data from the BRIDGE Phase III Open Label Switch-Over Study of pegunigalsidase alfa for the Treatment of Fabry Disease 12-Months On-treatment Data Indicate Sig
Protalix BioTherapeutics Announces Positive 12-Month Interim Data from the BRIDGE Phase III Open Label Switch-Over Study of pegunigalsidase alfa for the Treatment of Fabry Disease 12-Months On-treatment Data Indicate Significant Improvement in Kidney Function in Patients Swi
Read more →PLXProtalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease Phase III BALANCE study now fully enrolled BLA subm
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease Phase III BALANCE study BLA submission anticipated in Q1 2020 through FDA accelerated approval pathway CA
Read more →PLXProtalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American
Protalix BioTherapeutics has received a deficiency letter from NYSE American due to non-compliance with listing standards, specifically related to stockholders' equity and net losses. The company plans to submit a compliance plan within 18 months to address these issues. Despite this setback, Protalix's stock will continue to trade while they work on regaining compliance.
Read more →PLXProtalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships
Protalix BioTherapeutics is engaging a financial advisory firm to explore strategic alternatives aimed at maximizing shareholder value. The company is focused on improving its capital structure and pursuing partnerships for its pipeline candidates, including OPRX-106 and alidornase alfa. Despite positive initiatives, Protalix faces significant risks related to funding and regulatory approvals.
Read more →PLXShlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
Shlomo Yanai has resigned as Chairman of Protalix BioTherapeutics for personal reasons, effective immediately. Zeev Bronfeld, an independent director and long-time investor, has been elected as the new Chairman. Yanai's leadership was pivotal in the development of the company's drug candidate for Fabry disease, currently in phase III trials.
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update CARMIEL, Israel, August 8, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercial
Read more →PLXProtalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019
Protalix BioTherapeutics will hold a conference call on August 8, 2019, to discuss its second quarter financial results and provide a corporate update. The call will be accessible via phone and online, allowing investors to participate and stay informed about the company's developments. Protalix is known for its innovative plant cell-based expression system for therapeutic proteins.
Read more →PLXProtalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
Protalix BioTherapeutics has appointed Eyal Rubin as the new Senior Vice President and Chief Financial Officer, effective September 22, 2019. Rubin, who has over 20 years of experience in finance and capital markets, expressed excitement about joining the team and contributing to the company's development. Yossi Maimon, the outgoing CFO, will assist in the transition.
Read more →PLXProtalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
Protalix BioTherapeutics has completed enrollment in the Phase III BRIGHT clinical trial for pegunigalsidase alfa (PRX-102), targeting Fabry disease. This trial aims to evaluate the safety and efficacy of a less frequent dosing regimen compared to current treatments. The study involves up to 30 patients previously treated with enzyme replacement therapies and will assess various health parameters over a 12-month period.
Read more →PLXProtalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States BLA Submission Expected First Quarter 2020
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the BLA Submission Expected CARMIEL, Israel, June 6, 2019 (GLOBENEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:
Read more →PLXProtalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
Protalix BioTherapeutics has appointed Dror Bashan as its new President and CEO, effective June 30, 2019, succeeding Moshe Manor, who is stepping down for personal reasons. Bashan, with over 20 years in the pharmaceutical industry, aims to leverage his experience to advance the company's development pipeline. Manor will assist in the transition and continue as a consultant.
Read more →PLXProtalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update CARMIEL, Israel, May 6, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercializati
Read more →PLXProtalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization
Read more →PLXProtalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15 th Annual WORLD Symposium TM 2019 ~Pharmacokinetic data from patients treated
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposiumTM 2019 ~Pharmacokinetic data from patients treated in the study show that infusion of pegunigalsidase alfa e
Read more →PLXProtalix BioTherapeutics Corporate Update January 2019 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securitie
Protalix BioTherapeutics Corporate Update January 2019 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward - looking s
Read more →PLXProtalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease CARMIEL, Israel, December 17, 2018 (GLOBENEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX
Read more →PLXProtalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update CARMIEL, Israel, November 7, 2018 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercializat
Read more →PLXProtalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018 ~Preliminary Results I
Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018 Results Indicate Significant Improvement in Kidney Function in Patients Switch
Read more →PLXProtalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease ~Preliminary Results Indicate Improvement in Kidney Function in Patients Switche
Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal ) to pegunigalsidase alfa deteriora
Read more →PLXProtalix BioTherapeutics Appoints David Granot to its Board of Directors Carmiel, Israel
Protalix BioTherapeutics Appoints David Granot to its Board of Directors Carmiel, Israel, August 13, 2018 /GlobeNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company's Board of Directors has appointed Mr. David Granot to s
Read more →PLXProtalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update
Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update CARMIEL, Israel, August 9, 2018 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercializati
Read more →PLXProtalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Protal
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase for the Treatment of Fabry Disease receive $25 million upfront, an additional up to $20 million in deve
Read more →PLXProtalix Announces Exchange and Discharge of Remaining 2018 Notes
Exchange and Discharge of Remaining 2018 Notes CARMIEL, Israel, May 24, 2018 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (the "Company") (NYSE American: PLX) (TASE:PLX) announced today that $3.42 million of the aggregate principal amount of the Company's outstanding 4.5%
Read more →PLXProtalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update
Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update CARMIEL, Israel, May 9, 2018 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization o
Read more →PLXProtalix BioTherapeutics Corporate Update March 2018 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities
Protalix BioTherapeutics Corporate Update March 2018 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward - looking st
Read more →PLXProtalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update Enrollment in all Fabry Trials is ongoing in over Forty Active Sites Current Cash is Projected to Fund the Company through Clinical Tr
Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update all Fabry Trials is ongoing in over Forty Active Sites is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020 CARMIEL, Israel, March 6, 2018 - GlobeNewswire /Protal
Read more →PLXProtalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration Fast Track designation highlights high unmet medical need in the treatment of Fabry disease
Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration Fast Track designation highlights high unmet medical need in the treatment of Fabry disease CARMIEL, Israel, January 31, 2018 (GLOBE NEWSWIRE) -- Protal
Read more →PLXProtalix BioTherapeutics Corporate Update January 2018 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securiti
Protalix BioTherapeutics Corporate Update January 2018 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward - looking
Read more →PLXProtalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference Continued to Demonstrate Improvement across all Key Fabry Dis
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment
Read more →PLXProtalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union CARMIEL, Israel, November 13, 2017 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical
Read more →PLXProtalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update Collaboration Agreement with Chiesi Farmaceutici Further Validates Fabry Program and Significantly Improves Financial Position Suf
Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update Agreement with Chiesi Farmaceutici Further Validates Fabry Program and Significantly Improves Financial Position Resources to Fund Operations into 2020 Further Strengthened by the Reduct
Read more →PLXProtalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Protalix grants
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Chiesi Ex-US rights to PRX-102, a chemically modified version of the reco
Read more →PLXProtalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update Cystic Fibrosis Foundation Approves Letter of Application Enabling Protalix to Apply for Grant Funding Debt Refinancing and Finan
Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update Foundation Approves Letter of Application Enabling Protalix to Apply for Grant Funding and Financing Significantly improves Financial Position CARMIEL, Israel, August 9, 2017 -- GlobeNe
Read more →PLXProtalix BioTherapeutics Completes Private
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022 Concurrently the Company Completes Private Placement of $10 Million Convertible Notes CARMIEL, Israel, July 25, 2017 //GlobeNews
Read more →PLXProtalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40 th European Cystic Fibrosis Society Conference New clinical data reported on ppFEV1 measuremen
Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society New clinical data reported on ppFEV1 measurement taken after washout of alidornase alfa demonstrates meaningful decr
Read more →PLXProtalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First E
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development Monthly Dosing Trial in Fabry Patients to Commence Next Quarter in the Commercia
Read more →PLXProtalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease Once Monthly Dosing Would Represent a 50% Reduction in
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease Once Monthly Dosing Would Represent a 50% Reduction in Patient Infusions Unique Chemical Modifications to pegu
Read more →PLXProtalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Rep
Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies Israel, April 18, 2017 -- Protalix Bio
Read more →PLXProtalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase TM ) for the Treatment of Cystic Fibrosis Positive Results in a Number of Clinically Relevant Parameters Sugg
Protalix BioTherapeutics Announces Positive from Phase II Clinical Trial of alidornase alfa (AIR DNaseTM) for the Treatment of Cystic Fibrosis Positive Results in a Number of Clinically Relevant Parameters Suggest Improved Lung Function with alidornase alfa CARMIEL, Israel,
Read more →PLXProtalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update Current Cash is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019
Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019 CARMIEL, Israel, March 16, 2017 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX
Read more →PLXProtalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017 Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream
Protalix BioTherapeutics Provides Review and Strategic Outlook for 2017 Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream Fabry Phase III Clinical Trial Underway with Interim Results Ex
Read more →PLXProtalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase TM ) for the Treatment of Cystic Fibrosis
Protalix BioTherapeutics Announces Positive from Phase II Clinical Trial of alidornase alfa (AIR DNaseTM) for the Treatment of Cystic Fibrosis CARMIEL, Israel, January 3, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim result
Read more →PLXProtalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil Shipment Size for Fourth Quarter of 2017 Represents Annual Revenues of approximately $42 Million CARMIEL, Israel, December 27, 2016 //GlobeNe
Read more →PLXProtalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil CARMIEL, Israel, December 14, 2016 //GlobeNewswire - Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX) (the "Compa
Read more →PLXCompany Presentation December 2016 www.protalix.com 8 , 181 , 153 37 , 93 , 168 3 , 173 , 235 49 , 132 , 174 118, 206, 190 178, 213, 230 www.protalix.com Note Regarding Forward - Looking Statements This presentation cont
Company Presentation December 2016 www.protalix.com 8 , 181 , 153 37 , 93 , 168 3 , 173 , 235 49 , 132 , 174 118, 206, 190 178, 213, 230 www.protalix.com Note Regarding Forward - Looking Statements This presentation contains forward - looking statements . To the extent that stat
Read more →PLXProtalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis CARMIEL, Israel, November 30, 2016 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enroll
Read more →PLXAlfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older Approval further supports the advanced ongoing discussions with the Brazilian Ministry
Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alf
Read more →PLXProtalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results Patient Enrollment Ongoing for Phase III Fabry Clinical Trial with approximately 10 Patients Currently in Evaluation and Screening Stages En
Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results Patient Enrollment Ongoing for Phase III Fabry Clinical Trial with approximately 10 Patients Currently in Evaluation and Screening Stages Enrollment for the Phase II Cystic Fibrosis Clinical Tria
Read more →PLXProtalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease Six Sites Activated Across the United States and Europe with additional patients currently in
Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial
Read more →PLXProtalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease CARMIEL, Israel, August 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additio
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2016 Financial Results Patient Screening Underway for Fabry Phase III Clinical Trial Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results Patient Screening Underway for Fabry Phase III Clinical Trial Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End CARMIEL, Israel, August 8, 2016 -- Protalix BioTherapeutics,
Read more →PLXProtalix BioTherapeutics Announces First Patient Dosed in the AIR DNase TM Phase II Clinical Trial for Cystic Fibrosis
Protalix BioTherapeutics Announces First in the AIR DNaseTM Phase II Clinical Trial for Cystic Fibrosis CARMIEL, Israel, July 7, 2016 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the first patient has been dosed in the Company's phase II clinica
Read more →PLXProtalix BioTherapeutics Corporate Update June 2016 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities
Protalix BioTherapeutics Corporate Update June 2016 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward - looking sta
Read more →PLXProtalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings 24-Month Superiority Trial vs. Fabrazyme for a United States Filing At 12 Months,
Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings 24-Month Superiority Trial vs. Fabrazyme for a United States Filing At 12 Months, Interim Analysis of the Superiority Trial Data will be
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update Advanced Discussions with FDA regarding SPA for Phase III Clinical Trial of PRX-102 Expected to Commence around Mid-Year
Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update Advanced Discussions with FDA regarding SPA for Phase III Clinical Trial of PRX-102 Expected to Commence around Mid-Year Phase II Clinical Trial of PRX-110 in Cystic Fibrosis
Read more →PLXProtalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer Strong Cash Position of
Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018
Read more →PLXProtalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12 th Annual WORLD Symposium TM 2016 Demonstrated Effectiveness Across All Diseas
Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposiumTM 2016 Demonstrated Effectiveness Across All Disease Parameters including Cardiac and Kidney Functions PRX-1
Read more →PLXPRX - 102 prh - Galactosidase - A Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease 1 11/23/2015 1 This presentation contains forward - looking statements within the meaning of Section 27A
PRX - 102 prh - Galactosidase - A Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease 1 11/23/2015 1 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
Read more →PLXProtalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting with FDA Clear Path for Biologics License Application (BLA) Submi
Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting with FDA Clear Path for Biologics License Application One Short-Term Safety and Efficacy Study Required to Support Full
Read more →PLXProtalix BioTherapeutics Reports Third Quarter 2015 Financial Results Net losses narrowed Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively
Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product Candidates CARMIEL, Israel, November 9, 2015 -- Pro
Read more →PLXProtalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Ben
Protalix BioTherapeutics Reports Positive on PRX-102 for Fabry Disease Significantly Improved PK Characteristics Higher Active Enzyme Quantities, Induced Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters Reversal in eGFR Slope Achieved Suggesting I
Read more →PLXProtalix BioTherapeutics Sells its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a total of $46 Million Protalix to use funds to aggressively push its clinical pipeline forw
BioTherapeutics Sells its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a total to use funds to aggressively push its clinical pipeline forward and execute its new strategy of developing clinically superior receives all rights to
Read more →PLXProtalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease Positive efficacy data across all disease parameters Positive safety data with low level of ant
Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease Positive efficacy data across all disease Positive safety data with low level of antibody End of Phase II meeting with FDA scheduled CARMIEL, Israel,
Read more →PLXProtalix BioTherapeutics Reports Second Quarter 2015 Financial Results Net Losses narrowed with clinical progress in all three product candidates
Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results Net Losses narrowed with clinical progress in all three product candidates CARMIEL, Israel, August 10, 2015 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results fo
Read more →PLXProtalix BioTherapeutics Reports First Quarter 2015 Financial Results - Losses narrowed by 19% - Interim data and full results for PRX-102 expected in the Second Half of 2015
Protalix BioTherapeutics Reports First Quarter 2015 Financial Results - Losses narrowed by 19% - Interim data and full results for PRX-102 expected in the Second Half of 2015 CARMIEL, Israel, May 7, 2015 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today repo
Read more →PLXProtalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update
Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update CARMIEL, Israel, March 12, 2015 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the year ended December 31, 2014 and provided an
Read more →PLXProtalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium New Positive Clinical Data on Cardiac and Kidney Functions Detailed Positive Clin
BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium Positive Clinical Data on Cardiac and Kidney Functions Positive Clinical Data on All Disease Parameters CARMIEL, Israel, February 12, 2015 -- Prot
Read more →PLXProtalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease Interim Efficacy and Safety Results to be Presented at WORLD Symposium
BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease Efficacy and Safety Results to be Presented at WORLD Symposium CARMIEL, Israel, February 2, 2015 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that t
Read more →PLXProtalix BioTherapeutics Reports Positive Interim Data from Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters Favorable Sa
Protalix BioTherapeutics Reports Positive Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters Favorable Safety Profile CARMIEL, Israel, January 8, 2015 /GlobeNewswire /Protalix Bi
Read more →PLXProtalix BioTherapeutics Announces New Strategy for Accelerated Growth Prioritizing Pipeline Candidates to Focus on Bio-better Products with a Clear Competitive Advantage
Protalix BioTherapeutics Announces New Strategy for Accelerated Growth Prioritizing Pipeline Candidates to Focus on Bio-better Products with a Clear Competitive Advantage CARMIEL, Israel, January 5, 2015 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX)
Read more →PLXProtalix BioTherapeutics appoints Moshe Manor as President and Chief Executive Officer Carmiel, Israel
Protalix BioTherapeutics appoints Moshe Manor as President and Chief Executive Officer Carmiel, Israel, September 29, 2014 /Protalix BioTherapeutics, Inc. (NYSE MKT: PLX, TASE: PLX), announced today, that its Board of Directors has appointed Mr. Moshe Manor as its new Preside
Read more →PLX: Media Contact
For immediate release: Media Contact: August 28, 2014 Steven Danehy (212) 733-1538 steven.danehy@pfizer.com Investor Contact: Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO (tal
Read more →PLXProtalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors Carmiel, Israel
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors Carmiel, Israel, July 24, 2014 /GlobeNewswire / Protalix BioTherapeutics, Inc. (NYSE MKT: PLX, TASE: PLX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board
Read more →PLXProtalix Announces New Data on ELELYSO (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Protalix Announces New Data on ELELYSO (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting CARMIEL, Israel, June 27, 2014 /GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that new clinical da
Read more →PLXProtalix BioTherapeutics Initiates Phase II Study with PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Protalix BioTherapeutics Initiates Phase II Study with PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease CARMIEL, Israel, June 18, 2014 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that
Read more →PLXProtalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., will Retire this Year Board of Directors initiates succession process; Dr. Aviezer remains President and Chief Executive Officer unti
Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., will Retire this Year Board of Directors initiates succession process; Dr. Aviezer remains President and Chief Executive Officer until his successor is named Carmiel, Israel, June 13, 2014
Read more →PLXProtalix Announces ELELYSO (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
ELELYSO (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients CARMIEL, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE: PLX), announced today that Health Canada has granted
Read more →PLXProtalix Announces ELELYSO (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients
ELELYSO (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients CARMIEL, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Australian Therapeut
Read more →PLXProtalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014 CARMIEL, Israel, February 12, 2014 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the
Read more →PLXProtalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook Dr. Aviezer to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook Dr. Aviezer to Present at the 32nd Annual J.P. Morgan Healthcare Conference CARMIEL, Israel, January 13, 2014 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that Dr. D
Read more →PLXProtalix BioTherapeutics Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients
Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients CARMIEL, Israel, October 14, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today initial positive results from its pha
Read more →PLXProtalix BioTherapeutics Announces
Protalix BioTherapeutics Announces Closing of $69 Million Offering of Convertible Notes CARMIEL, Israel, September 18, 2013 //GlobeNewswire - Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX) announced the closing of its offering of $69 million principal amount of its 4.
Read more →PLXProtalix BioTherapeutics Announces Proposed $60 Million Offering of Convertible Notes
Protalix BioTherapeutics Announces Proposed $60 Million Offering of Convertible Notes CARMIEL, Israel, September 11, 2013 //GlobeNewswire - Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX) announced today that it intends, subject to market conditions, to offer and sell
Read more →PLXProtalix BioTherapeutics Discloses Three New Compounds in Development - Oral PRX-106 for immune mediated disorders - PRX-110 for Cystic Fibrosis (CF) - PRX-107 for emphysema due to hereditary alpha1-antitrypsin deficienc
Protalix BioTherapeutics Discloses Three New Compounds in Development - Oral PRX-106 for immune mediated disorders - PRX-110 for Cystic Fibrosis (CF) - PRX-107 for emphysema due to hereditary alpha1-antitrypsin deficiency CARMIEL, Israel, June 20, 2013 /GlobeNewswire /Protal
Read more →PLXProtalix BioTherapeutics and Brazil's Ministry of Health Enter into Supply and Technology Transfer Agreement for UPLYSO (alfataliglicerase) in Brazil Exclusive License and Supply Agreement with Pfizer amended to facilita
Protalix BioTherapeutics and Brazil's Ministry of Health Enter into Supply and Technology Transfer Agreement for UPLYSO (alfataliglicerase) in Brazil and Supply Agreement with Pfizer amended to facilitate the Technology Transfer CARMIEL, Israel, June 19, 2013 /GlobeNewswire
Read more →PLXProtalix BioTherapeutics to Host Analyst Event in New York City
Protalix BioTherapeutics to Host Analyst Event in New York CARMIEL, Israel, June 12, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), will be hosting an analyst event on Thursday, June 20, 2013 at 8:00 AM EDT in New York City. The meeting will feat
Read more →PLXUPLYSO (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO (alfataliglicerase) Approved for the Treatment of Gaucher Disease CARMIEL, Israel, April 29, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that the Mexican Federal Commission for the Protection against Sanitary Risk (COFE
Read more →PLXProtalix BioTherapeutics Treats First Gaucher Patient in Phase I Study with PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease
BioTherapeutics Treats First Gaucher Patient in Phase I Study with PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Israel, April 2, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that the first patient has been treated
Read more →PLX: Pfizer Contacts
For Immediate Release: Pfizer Contacts: March 18, 2013 Sharon Castillo (Media) 202-494-6769 Sharon.J.Castillo@pfizer.com Suzanne Harnett (Investors) 212-733-8009 Suzanne.Harnett@pfizer.com Protalix Contacts: Kari Watson (Media) MacDougall Biomedical Communicatio
Read more →PLXProtalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher patients with PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease
BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher patients with PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease Israel, March 7, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today tha
Read more →PLXProtalix Announces New Clinical Data on ELELYSO to be Presented at the WORLD Symposium 2013
Protalix Announces New Clinical Data on ELELYSO to be Presented at the WORLD Symposium 2013 CARMIEL, Israel, February 13, 2013/GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that new clinical data on ELELYSO (taliglucerase alfa) will be
Read more →PLXProtalix BioTherapeutics Reviewing Partnering and Other Alternatives
Protalix BioTherapeutics Reviewing Partnering and Other Alternatives CARMIEL, Israel, February 5, 2013 /Globes Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), confirms, in response to inquiries received this morning and a report appearing in the Israeli pres
Read more →PLXProtalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients with PRX-102
Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients with PRX-102 CARMIEL, Israel, December 10, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that the first patient has been treated in t
Read more →PLXProtalix BioTherapeutics Signs Clinical Development Agreement with Pfizer for ELELYSO TM (taliglucerase alfa)
Protalix BioTherapeutics Signs Clinical Development Agreement with Pfizer for ELELYSOTM (taliglucerase alfa) CARMIEL, Israel, December 6, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that it has entered into a Clinical Developm
Read more →PLXProtalix BioTherapeutics Receives Marketing Authorization for Elelyso TM for the Treatment of Gaucher Disease from the Israeli Ministry of Health
Protalix BioTherapeutics Receives Marketing Authorization for ElelysoTM for the Treatment of Gaucher Disease from the Israeli Ministry of Health CARMIEL, Israel, September 27, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that i
Read more →PLXProtalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients with PRX-102, a Modified Enzyme Replacement Therapy Phase I/II Clinical Trial to Initiate Enrollment of Fabry P
Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients with PRX-102, a Modified Enzyme Replacement Therapy Phase I/II Clinical Trial to Initiate Enrollment of Fabry Patients in the Fourth Quarter of 2012 CARMIEL, Israel,
Read more →PLXProtalix BioTherapeutics to Present at the Canaccord Genuity 32 nd Annual Growth Conference
Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference CARMIEL, Israel, August 9, 2012 / GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX),announced today that Yossi Maimon, the Company's Chief Financial Officer, will pr
Read more →PLXProtalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10 th Annual European Working Group on Gaucher Disease Meeting
Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European Working Group on Gaucher Disease Meeting CARMIEL, Israel, July 2, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that
Read more →PLXNew Clinical Data on ELELYSO (taliglucerase alfa) to be Presented at the 10 th Annual European Working Group on Gaucher Disease Meeting
New Clinical Data on ELELYSO (taliglucerase alfa) to be Presented at the 10th Annual European Working Group on Gaucher Disease Meeting CARMIEL, Israel, June 25, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that new clinical data
Read more →PLXProtalix BioTherapeutics to Review CHMP Opinion for ELELYSO Conference Call and Webcast Scheduled for Friday, June 22 at 9:00
Protalix BioTherapeutics to Review CHMP Opinion for ELELYSO Conference Call and Webcast Scheduled for Friday, June 22 at 9:00 AM EDT CARMIEL, Israel, June 22, 2012/GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today the Company has scheduled
Read more →PLXProtalix Receives a $25 Million Milestone Payment for U.S. Approval of ELELYSO CARMIEL, Israel, June 11 , 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that it has received
Receives a $25 Million Milestone Payment for U.S. Approval of ELELYSO Israel, June 11, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX), announced today that it has received a $25 million milestone payment from Pfizer Inc. as part of the companies'
Read more →PLXProtalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
Protalix BioTherapeutics to Present at Three Upcoming Healthcare CARMIEL, Israel, May 29, 2012 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that senior management will present at three upcoming conferences. Details regarding the con
Read more →PLXPfizer and Protalix BioTherapeutics Announce
For Immediate Release: Joan Campion (Media) Joan.Campion@Pfizer.com Suzanne.Harnett@Pfizer.com Jennifer Conrad (Media) MacDougall Biomedical Communications jconrad@macbiocom.com Marcy Nanus (Investors) The Trout Group, LLC Mnanus@troutgroup.com Pfizer and Protalix BioTh
Read more →PLXProtalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders CARMIEL, Israel, March 16, 2012/GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that its board of directors has set May 5, 2012, as the record date for shareho
Read more →PLXProtalix BioTherapeutics to Participate at Two Upcoming Global Healthcare Conferences
Protalix BioTherapeutics to Participate at Two Upcoming Global Healthcare Conferences CARMIEL, Israel, February 23, 2012/Globe Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Yossi Maimon, the Company's Vice President and Chief Financia
Read more →PLXProtalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock
Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock CARMIEL, Israel, February 16, 2012 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today the pricing of its previously announced underwritten public offering of
Read more →PLXProtalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium CARMIEL, Israel, February 9, 2012/GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that new clinical data on talig
Read more →PLXProtalix BioTherapeutics to Present at the Oppenheimer 22nd Annual Healthcare Conference
Protalix BioTherapeutics to Present at the Oppenheimer 22nd Annual Healthcare Conference CARMIEL, Israel, December 13, 2011 /GlobeNewswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executiv
Read more →PLXFDA Extends taliglucerase alfa PDUFA Date to
FDA Extends taliglucerase alfa PDUFA Date to May 1, 2012 CARMIEL, Israel, December 6, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the FDA has exten
Read more →PLXProtalix Announces Successful European GMP Audit
Protalix Announces Successful European GMP Audit CARMIEL, Israel, December 1, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that the Irish Medicines Board (IMB) has completed a successful GMP (Good Manufacturing Practice) audit of th
Read more →PLXProtalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease
Protalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease CARMIEL, Israel, Nov 10, 2011. Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX) announced today that a paper entitled: "Adaptive alternative splicing correlates with les
Read more →PLXProtalix BioTherapeutics to Present at Four Upcoming Conferences
Protalix BioTherapeutics to Present at Four Upcoming Conferences CARMIEL, Israel, October 26, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that senior management will present at four upcoming conferences: Ernst & Young Journey 2011
Read more →PLXProtalix BioTherapeutics to Present at the Jefferies 2011 Global Healthcare Conference
Protalix BioTherapeutics to Present at the Jefferies 2011 Global Healthcare Conference CARMIEL, Israel, September 21, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Yossi Maimon, the Company's Chief Financial Officer, will presen
Read more →PLXProtalix BioTherapeutics to Present at the UBS Global Life Sciences Conference
Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference CARMIEL, Israel, September 13, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer,
Read more →PLXProtalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood , the Journal of the American Society of Hematology
Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology CARMIEL, Israel, September 8, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that an article entitled
Read more →PLXProtalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA date
Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA date CARMIEL, Israel, August 17, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that the U.S. Food & Dru
Read more →PLXProtalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial
Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial CARMIEL, Israel, August 1, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that it has submi
Read more →PLXProtalix Announces Successful GMP Manufacturing Audit by Brazil's National Health Surveillance Agency
Protalix Announces Successful GMP Manufacturing Audit by Brazil's National Health Surveillance Agency CARMIEL, Israel, June 15, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Brazil's National Health Surveillance Agency ("Ag ncia
Read more →PLXProtalix BioTherapeutics to Present at Four Upcoming Healthcare Conferences
Protalix BioTherapeutics to Present at Four Upcoming Healthcare Conferences CARMIEL, Israel, May 12, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that members of the Company s senior management will present the Company s corporate
Read more →PLXProtalix BioTherapeutics to Present at the Bio-Manguinhos International Symposium on Immunobiologicals in Brazil and the 2011 ILSI-Biomed Conference in Israel
Protalix BioTherapeutics to Present at the Bio-Manguinhos International Symposium on Immunobiologicals in Brazil and the 2011 ILSI-Biomed Conference in Israel CARMIEL, Israel, April 27, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today
Read more →PLXProtalix Biotherapeutics to Present at the Tel Aviv Stock Exchange 100 Investment Conference
Protalix Biotherapeutics to Present at the Tel Aviv Stock Exchange 100 Investment Conference CARMIEL, Israel, April 7, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that Yossi Maimon, the Company s Chief Financial Officer, will pres
Read more →PLXProtalix to Present New Data on taliglucerase alfa and Preclinical Data on Oral Enzyme glucocerebrosidase at the WORLD Lysosomal Disease Network Symposium
Protalix to Present New Data on taliglucerase alfa and Preclinical Data on Oral Enzyme glucocerebrosidase at the WORLD Lysosomal Disease Network Symposium CARMIEL, Israel, February 18, 2011/PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today th
Read more →PLXProtalix BioTherapeutics January 2011 Confidential Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amend
Certain limited capped expenses Territories Pfizer retains exclusive worldwide rights outside of Israel Protalix retains exclusive commercialization rights in Israel (1) Manufacturing Protalix to manufacture taliglucerase alfa Commercialization Strategy: Collaboration 21 (1) Prot
Read more →PLXProtalix Announces Oral Presentations at the WORLD Lysosomal Disease Network Symposium
Protalix Announces Oral Presentations at the WORLD Lysosomal Disease Network Symposium CARMIEL, Israel, January 24, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that clinical data from the switchover trial of taliglucerase alfa in
Read more →PLXProtalix BioTherapeutics Presents Data on the Company s Fabry Program and Oral Enzyme Gaucher Program with Experts in the Field of Lysosomal Disorders
Protalix BioTherapeutics Presents Data on the Company s Fabry Program and Oral Enzyme Gaucher Program with Experts in the Field of Lysosomal Disorders CARMIEL, Israel, January 19, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that
Read more →PLXProtalix BioTherapeutics Announces Presentation of PRX-105 Data at the BARDA Industry Day
Protalix BioTherapeutics Announces Presentation of PRX-105 Data at the BARDA Industry Day CARMIEL, Israel, January 4, 2011 (PR NEWSWIRE) Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today that it has been invited to deliver an oral presentation on PRX-105
Read more →PLXPfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease New York, NY / Carmiel, Israel
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease New York, NY/Carmiel, Israel, November 29, 2010 Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX,
Read more →PLXProtalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa CARMIEL, Israel, November 2, 2010 (PR NEWSWIRE) Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX), announced today positive preliminary data from the first 15 patients that com
Read more →PLXProtalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences CARMIEL, Israel, October 25, 2010 Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX), announced today that Dr. David Aviezer, the Company s President and Chief Executive Officer, will present at
Read more →PLXProtalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer CARMIEL, Israel, September 7, 2010 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) today announced the appointment of Mr. Tzvi Palash as the Company s Chief Operating Officer. In this newly created position, Mr
Read more →PLXProtalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange - Common Stock to List on both Tel Aviv Stock Exchange and the NYSE Amex Beginning Monday
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange - Common Stock to List on both Tel Aviv Stock Exchange and the NYSE Amex Beginning Monday, September 6, 2010 under the Ticker Symbol PLX - Company Anticipates Joining TASE s TA-75, TA-100, Tel-Tech, Tel-Tech 15 a
Read more →PLXPROTALIX BIOTHERAPEUTICS ANNOUNCES FRENCH ATU GRANTED FOR TALIGLUCERASE ALFA FOR THE TREATMENT OF GAUCHER DISEASE CARMIEL, Israel, July 13 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that the French r
PROTALIX BIOTHERAPEUTICS ANNOUNCES FRENCH ATU GRANTED FOR TALIGLUCERASE ALFA FOR THE TREATMENT OF GAUCHER DISEASE CARMIEL, Israel, July 13 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that the French regulatory authority has granted an Autorisation Temporair
Read more →PLXProtalix BioTherapeutics Receives PDUFA Date for taliglucerase alfa CARMIEL, Israel, July 12 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Company s New Drug Application (NDA) for taligluceras
Protalix BioTherapeutics Receives PDUFA Date for taliglucerase alfa CARMIEL, Israel, July 12 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Company s New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and
Read more →PLXProtalix BioTherapeutics Completes Phase I Clinical Trial for PRX-105
Protalix BioTherapeutics Completes Phase I Clinical Trial for PRX-105 CARMIEL, Israel, June 8, 2010 /PRNewswire-FirstCall/ Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today the completion of its phase I clinical trial of PRX-105, a plant cell expressed pegylated
Read more →PLXProtalix BioTherapeutics Receives Research Grant of up to $4.1 Million From the Israeli Government s Office of the Chief Scientist
Protalix BioTherapeutics Receives Research Grant of up to $4.1 Million From the Israeli Government s Office of the Chief Scientist CARMIEL, Israel, May 17, 2010 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX), announced today that the Office of the Chief Scient
Read more →PLXProtalix Submits Validation Data on Manufacturing Process to FDA CARMIEL, Israel, April 27 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today it has submitted validation data regarding the Company s manufac
Protalix Submits Validation Data on Manufacturing Process to FDA CARMIEL, Israel, April 27 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today it has submitted validation data regarding the Company s manufacturing process for taliglucerase alfa to the U.S. Food an
Read more →PLXProtalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications CARMIEL, Israel, March 17: Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I cl
Protalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications CARMIEL, Israel, March 17: Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company s plant cell expresse
Read more →PLXProtalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors CARMIEL, Israel, March 9 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that Mr. Eli Hurvitz is relinquishing his position
Protalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors CARMIEL, Israel, March 9 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that Mr. Eli Hurvitz is relinquishing his position as Chairman and member of the Board of Directors of the C
Read more →PLXProtalix Announces Successful GMP Manufacturing Audit by Israel s Ministry of Health
Protalix Announces Successful GMP Manufacturing Audit by Israel s Ministry of Health CARMIEL, Israel, March 3, 2010 Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that the Israeli Ministry of Health has completed a successful GMP (Good Manufacturing Practice)
Read more →PLXProtalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium
Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium CARMIEL, Israel, February 11, 2010 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that additional data from the Company s pivotal Phase III clinical trial
Read more →PLXProtalix Announces Presentation of Phase III taliglucerase alfa Data at WORLD Lysosomal Disease Network
Protalix Announces Presentation of Phase III taliglucerase alfa Data at WORLD Lysosomal Disease CARMIEL, Israel, February 4, 2010 Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with G
Read more →PLXProtalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease
Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease CARMIEL, Israel, February 2, 2010 Protalix BioTherapeutics, Inc. (NYSE- Amex: PLX) announced today that, in connection with the New Drug Application (NDA) filed by the Company
Read more →PLXEuropean Medicines Agency s COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix s taliglucerase alfa
European Medicines Agency s COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix s taliglucerase alfa CARMIEL, Israel, January 13, 2010 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that the Committee for Orphan Medicinal
Read more →PLXProtalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs CARMIEL, Israel, December 17, 2009 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) today announced the appointment of Sandra Lauterbach to Vice President, Sales and Commercial Affairs. In this newl
Read more →PLXProtalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher s Disease CARMIEL, Israel (BUSINESS WIRE) Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX) today announced the completion of its New Dr
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher s Disease CARMIEL, Israel (BUSINESS WIRE) Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX) today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Dru
Read more →PLXProtalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO for the Treatment of Gaucher Disease
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO for the Treatment of Gaucher Disease CARMIEL, Israel, October 15, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today positive top-line re
Read more →PLXProtalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug CARMIEL, Israel, September 22, 2009 (Business Wire) Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel ). Pro
Read more →PLXProtalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease Top-line Data Expected in October 2009
Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease Top-line Data Expected in October 2009 CARMIEL, Israel, September 14, 2009 (Business Wire) Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase I
Read more →PLXFDA Grants Protalix Orphan Drug Designation for prGCD
FDA Grants Protalix Orphan Drug Designation for prGCD CARMIEL, Israel, September 8, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA s Office of Orphan
Read more →PLXProtalix Receives FDA Fast Track Designation for prGCD
Protalix Receives FDA Fast Track Designation for prGCD CARMIEL, Israel August 25, 2009 (BUSINESS WIRE) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for prGCD, the Co
Read more →PLXU.S. Food and Drug Administration Approves Protalix s Treatment Protocol for prGCD
U.S. Food and Drug Administration Approves Protalix s Treatment Protocol for prGCD CARMIEL, Israel, August 17, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company s treat
Read more →PLXProtalix Holds Pre-NDA Meeting with FDA for prGCD
Protalix Holds Pre-NDA Meeting with FDA for prGCD CARMIEL, Israel, July 14, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that the Company held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting
Read more →PLXProtalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD
Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD CARMIEL, Israel, July 6, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that
Read more →PLXProtalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension Trial of prGCD
Protalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension CARMIEL, Israel, June 25, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX), announced today the initiation of a home care treatment program for patients enrolled
Read more →PLXFrost Sullivan Presents Protalix Biotherapeutics with its 2009 European Orphan Diseases Market Product Innovation of the Year Award
Frost Sullivan Presents Protalix Biotherapeutics with its 2009 European Orphan Diseases Market Product Innovation of the Year Award CARMIEL, Israel, June 4, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX), announced today that Frost Sullivan has presented t
Read more →PLXProtalix BioTherapeutics Receives Research Grant of over $6 million from the Israeli Government s Office of the Chief Scientist
Protalix BioTherapeutics Receives Research Grant of over $6 million from the Israeli Government s Office of the Chief Scientist CARMIEL, Israel, March 11, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE Alternext US:PLX), announced today that the Office of the Chief
Read more →PLXProtalix BioTherapeutics to Present at the WORLD Lysosomal Disease Network Symposium 2009
Protalix BioTherapeutics to Present at the WORLD Lysosomal Disease Network Symposium 2009 CARMIEL, Israel, February 13, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (AMEX: PLX), today announced that Dr. Einat Brill Almon, the Company s Senior Vice President of Product D
Read more →PLXProtalix BioTherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease
Protalix BioTherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease CARMIEL, Israel, December 19, 2008 (Business Wire) Protalix BioTherapeutics, Inc. (Amex: PLX), announced today enrollment of the first patien
Read more →PLXProtalix BioTherapeutics to Present at the Piper Jaffray 20th Annual Health Care Conference
Protalix BioTherapeutics to Present at the Piper Jaffray 20th Annual Health Care Conference CARMIEL, Israel, November 25, 2008 Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that Dr. David Aviezer, President and CEO, will present at the Piper Jaffray 20th Annual H
Read more →PLXProtalix BioTherapeutics to Present at to Present at Oppenheimer Annual Healthcare Conference and at Barclays Capital Small Mid-Cap Health Care Conference
Protalix BioTherapeutics to Present at to Present at Oppenheimer Annual Healthcare Conference and at Barclays Capital Small Mid-Cap Health Care Conference CARMIEL, Israel, October 28, 2008 (Business Wire) Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that Dr. Dav
Read more →PLXProtalix BioTherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference
Protalix BioTherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference CARMIEL, Israel, July 31, 2008 (Business Wire) Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it will present at the Oppenheimer Small and Mid Cap Clini
Read more →PLXProtalix BioTherapeutics to Present at UBS Global Life Sciences Conference
Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference CARMIEL, Israel September 19, 2007 Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that Dr. David Aviezer, its President and Chief Executive Officer, will present at the UBS Global Life Sci
Read more →PLXProtalix BioTherapeutics Added to Russell 3000 Index Carmiel, Israel
BioTherapeutics Added to Russell 3000 Index Carmiel, Israel June 26, 2007 Protalix BioTherapeutics, Inc. (AMEX: PLX) today announced that its shares have been added to the broad market Russell 3000 Index. The Russell Investment Group reconstituted its comprehensive set of U.S
Read more →PLXProtalix BioTherapeutics Plans to Offer Common Stock to the Public Carmiel, Israel
BioTherapeutics Plans to Offer Common Stock to the Public Carmiel, Israel June 20, 2007 Protalix BioTherapeutics, Inc. (AMEX: PLX), announced today that its Board of Directors has authorized it to prepare and file with the Securities and Exchange Commission a registration sta
Read more →PLXProtalix BioTherapeutics Appoints Dr. Ernest Beutler to its Scientific Advisory Board Carmiel, Israel
BioTherapeutics Appoints Dr. Ernest Beutler to its Scientific Advisory Board Carmiel, Israel June 4, 2007 - Protalix BioTherapeutics, Inc. (AMEX: PLX), today announced the appointment of Professor Ernest Beutler, M.D., to its Scientific Advisory Board. Professor Beutler serve
Read more →PLXProtalix BioTherapeutics to Present at the BIO International Convention on
BioTherapeutics to Present at the BIO International Convention on May 7, 2007 CARMIEL, Israel, May 3, 2007 - Protalix BioTherapeutics (AMEX: PLX) today announced that Dr. David Aviezer, President and Chief Executive Officer, will present at the Biotechnology Industry Organizat
Read more →PLXProtalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD Phase III clinical trial may commence shortly Carmiel, Israel
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD Phase III clinical trial may commence shortly Carmiel, Israel - April 18, 2007 - Protalix BioTherapeutics, Inc. (AMEX: PLX) today announced that it has received writt
Read more →PLXProtalix BioTherapeutics, Inc. to Commence Trading on the American Stock Exchange Shares to Trade under the Symbol PLX Carmiel, Israel
Protalix BioTherapeutics, Inc. to Commence Trading on the American Stock Exchange Shares to Trade under the Symbol PLX Carmiel, Israel - March 9, 2007 - Protalix BioTherapeutics, Inc. (OTC Bulletin Board: PXBT) today announced that its common stock has been approved for listi
Read more →PLXOrthodontix Announces Name Change to Protalix BioTherapeutics, Inc. Carmiel, Israel
Orthodontix Announces Name Change to Protalix BioTherapeutics, Inc. Carmiel, Israel, March 1, 2007 /PRNewswire/ -- Orthodontix, Inc. (OTC Bulletin Board: PXBT - News; "Orthodontix") today announced that it has changed its name to Protalix BioTherapeutics, Inc. The trading symb
Read more →Competitive Position
How PLX ranks across every disease it competes inCompetitive Position is a premium feature
See how PLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial